Samabriva, a plant-based biotechnology company, completed a Series-A round of financing to secure an investment of nearly €4 million. Its plant-based bioproduction process has the potential to transform production of high value molecules – such as natural active molecules (secondary metabolites) and recombinant proteins – for the pharmaceutical and cosmetic sectors. The immediate focus will be on the production of active pharmaceutical ingredients (API) using confined and controll...